Literature DB >> 9821017

Metabolic capacities in cultured human hepatocytes obtained by a new isolating procedure from non-wedge small liver biopsies.

P David1, C Viollon, E Alexandre, A Azimzadeh, L Nicod, P Wolf, D Jaeck, K Boudjema, L Richert.   

Abstract

A new isolating procedure of human hepatocytes has been developed using two-step collagenase digestion by a non-perfusion procedure (NP) of non-wedge liver biopsies. 1. A yield of 2-7 x 10(6) hepatocytes/g liver, 52-95% viability and 13-75% attachment were obtained from liver biopsies weighing 6-60 g, comparable to that obtained when using the classical perfusion procedure (P) to isolate human hepatocytes from wedge liver samples of 50-150 g. 2. In culture, human hepatocytes obtained by NP remained attached to plastic for up to 5 days and displayed the usual morphological characteristics. Their metabolic capacities, assessed by liver-specific albumin and urea synthesis and by CYP-dependent and conjugation pathways, were equivalent to those of human hepatocytes obtained by P. In addition, they responded adequately to specific CYP inducers, demonstrating that they constitute a model in which human drug metabolism and toxicity studies can be performed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9821017     DOI: 10.1177/096032719801701004

Source DB:  PubMed          Journal:  Hum Exp Toxicol        ISSN: 0960-3271            Impact factor:   2.903


  5 in total

1.  Strain difference (WKY, SPRD) in the hepatic antioxidant status in rat and effect of hypertension (SHR, DOCA). Ex vivo and in vitro data.

Authors:  D Binda; L Nicod; C Viollon-Abadie; S Rodriguez; A Berthelot; P Coassolo; L Richert
Journal:  Mol Cell Biochem       Date:  2001-02       Impact factor: 3.396

2.  Hepatocytes from alpha1B-adrenoceptor knockout mice reveal compensatory adrenoceptor subtype substitution.

Authors:  Clare Deighan; Alison M Woollhead; Janet F Colston; John C McGrath
Journal:  Br J Pharmacol       Date:  2004-06-21       Impact factor: 8.739

3.  Toll-like receptor dual-acting agonists are potent inducers of PBMC-produced cytokines that inhibit hepatitis B virus production in primary human hepatocytes.

Authors:  Ivan Hirsch; Jan Weber; Vaclav Janovec; Jan Hodek; Kamila Clarova; Tomas Hofman; Pavel Dostalik; Jiri Fronek; Jaroslav Chlupac; Laurence Chaperot; Sarah Durand; Thomas F Baumert; Iva Pichova; Barbora Lubyova
Journal:  Sci Rep       Date:  2020-07-29       Impact factor: 4.379

4.  Assessment of CYP-Mediated Drug Interactions for Evocalcet, a New Calcimimetic Agent, Based on In Vitro Investigations and a Cocktail Study in Humans.

Authors:  Kazuya Narushima; Hiroshi Maeda; Masanari Shiramoto; Yuichi Endo; Satoko Ohtsuka; Hiroaki Nakamura; Yoshinori Nagata; Tatsuo Uchimura; Ayako Kannami; Ryutaro Shimazaki; Masafumi Fukagawa; Tadao Akizawa
Journal:  Clin Transl Sci       Date:  2018-10-24       Impact factor: 4.689

Review 5.  Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies.

Authors:  M Teresa Donato; José V Castell
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 5.577

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.